Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens.
Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens.
复制标题
DOI：
10.2147/cpaa.s44377
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Matsumoto T
中科院分区：
文献类型：
--
作者：
Matsumoto T
硫酸阿贝卡星 (ABK) 是一种氨基糖苷类抗生素，于 1972 年被发现，衍生自地贝卡星，可稳定许多常见的氨基糖苷修饰酶。 ABK 不仅对革兰氏阳性菌（包括耐甲氧西林金黄色葡萄球菌 (MRSA)）表现出广泛的抗菌活性，而且对革兰氏阴性菌（如大肠杆菌、铜绿假单胞菌和肺炎克雷伯菌）也具有广泛的抗菌活性。 ABK自1990年起在日本被批准为注射制剂，商品名为Habekacin，用于治疗由MRSA引起的肺炎和败血症患者。该药物已用于超过 250,000 名患者，其临床疗效和安全性已在二十多年来得到证实。由于ABK与β-内酰胺组合具有协同作用，目前ABK有望用于治疗多重耐药革兰氏阴性细菌感染，例如铜绿假单胞菌和鲍曼不动杆菌的多重耐药菌株。
Arbekacin sulfate (ABK), an aminoglycoside antibiotic, was discovered in 1972 and was derived from dibekacin to stabilize many common aminoglycoside modifying enzymes. ABK shows broad antimicrobial activities against not only Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) but also Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. ABK has been approved as an injectable formulation in Japan since 1990, under the trade name Habekacin, for the treatment of patients with pneumonia and sepsis caused by MRSA. The drug has been used in more than 250,000 patients, and its clinical benefit and safety have been proven over two decades. ABK currently shows promise for the application for the treatment of multidrug-resistant Gram-negative bacterial infections such as multidrug-resistant strains of P. aeruginosa and Acinetobacter baumannii because of its synergistic effect in combination with beta-lactams.